Monitoring of Emicizumab using a Two-stage chromogenic tenase platform: assay Development and Validation

Scientific Research Question: Emicizumab is a factor VIII-(FVIII)-mimetic humanized antibody which was approved by the US FDA and European Commission for treatment of haemophilia A patients with inhibitors. To evaluate the efficiency of emicizumab therapy in hemophilia patients, an APTT-based one-stage assay is established to determine the plasma level of emicizumab. Our scientific question is if a two-stage chromogenic assay based on human...